Table 8.
NAR status after NACT for each arm.
| NAR status | Arm 1 |
Arm 2 |
|---|---|---|
| FOLFOX + Bevacizumab |
FOLFOXIRI + Bevacizumab |
|
| N = 10 | N = 10 | |
| NAR status | ||
| Low (NAR<8) | 0 (0%) | 5 (50%) |
| Intermediate (NAR ≥8 – NAR ≤16) | 4 (40%) | 3 (30%) |
| High (NAR>16) | 4 (40%) | 2 (20%) |
| Not evaluablea | 2 (20%) | 0 (0%) |
Note: Patients 1 (Arm B FOLFOXIRI + Bevacizumab) and 17 (Arm A FOLFOX + Bevacizumab) did not receive all planned cycles of chemotherapy.
a
NAR score for patient 7 and 9 could not be calculated as they did not undergo surgery.